ProCE Banner Activity

Phase II KarMMa-2 Cohort 2a: Idecabtagene Vicleucel in Patients With Multiple Myeloma With Early Relapse After Frontline ASCT

Slideset Download
Conference Coverage

Ide-cel demonstrated deep responses and manageable toxicity in patients with clinical high-risk MM and early relapse after first-line induction, ASCT, and lenalidomide maintenance.

Released: December 13, 2022

Expiration: December 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen